VIRI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response...

Stats
Today's Volume	197 373
Average Volume	306 964
Market Cap	8.19M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.0800 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.520
ATR14	$0.00600 (1.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-26	Pridgen William	Buy	2 917	Stock Option (right to buy)
2024-02-26	Thomas John C	Buy	4 167	Stock Option (right to buy)
2024-02-26	Whitley Richard James	Buy	4 000	Stock Option (right to buy)
2024-02-26	Keefer David R	Buy	4 709	Stock Option (right to buy)
2024-02-26	Burch Richard Alan	Buy	2 917	Stock Option (right to buy)

INSIDER POWER
99.86
Last 92 transactions
Buy: 2 833 595 \| Sell: 299 106

Volume Correlation

Long: -0.01 (neutral)

Short: -0.65 (weak negative)

Signal:(51.167) Neutral

Virios Therapeutics, LLC Correlation

10 Most Positive Correlations
BOCH	0.83
RDI	0.814
SHSP	0.814

10 Most Negative Correlations
GLPG	-0.857
GAINL	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Virios Therapeutics, LLC Correlation - Currency/Commodity

-0.49
( neutral )

-0.58
( weak negative )

0.00
( neutral )

0.24
( neutral )

Virios Therapeutics, LLC Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.280

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0573

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0647

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0783

Financial Reports:

No articles found.

Virios Therapeutics, LLC

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.